Date: 2012-10-25
Type of information: R&D agreement
Compound: lead compounds against epigenetic pathway targets
Company: Red Glead Discovery (Sweden) SARomics Biostructures (Sweden)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: SARomics Biostructures and Red Glead Discovery have entered into a drug discovery collaboration. Within the alliance, the two companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets. Targeting proteins involved in epigenetic mechanisms (the cellular processes associated with the modification of chromatin) have emerged as an important new therapeutic opportunity for treating cancer, diabetes, inflammatory diseases and more.By merging the complementary capabilities of the two companies, an efficient and versatile fragment-based lead discovery (FBLD) platform is enabled. The advanced structural biology platform and expertise contributed by SARomics Biostructures are combined with the bioassay technology and medicinal chemistry skills of Red Glead Discovery. The scientific excellence of the alliance is reflected by the track record of Red Glead Discovery for delivery of lead compounds and the established platform for structure-based drug design implemented by SARomics Biostructures.
Red Glead Discovery is a small molecule lead discovery company founded in 2011 as a spin-out from AstraZeneca and is privately owned. Red Glead Discovery offers first-rate contract drug discovery services and generates new commercial drug discovery projects (co-developed with academic and/or financing partners). The company provides access to cross-disciplinary expertise of high scientific standard within medicinal and analytical chemistry, assay development and screening, radioisotope labeling, as well as physicochemical and metabolic profiling.
SARomics Biostructures is the leading Scandinavian provider of structural biology and in silico drug discovery services. The company accelerates its customers’ drug discovery processes by providing structure-based drug design support including protein crystallization, X-ray protein structure determination, computational chemistry, protein modeling and NMR spectroscopy analyses.
Financial terms: For the project, the companies will share costs and the generated intellectual property rights. Project progress and the discovery of lead compounds will be effectuated by utilisation of FBLD, which is a powerful alternative to costly and resource-intensive high-throughput screening (HTS) campaigns. At this stage of the project, the collaboration will be run without external financing.
Latest news:
